Skip to content
The Skin Doctor

Melanocytic hyperplasia is a pathology-report term for an increased or altered number of melanocytes (pigment cells) in a biopsied mole. It is a description, not a single diagnosis — often benign, but sometimes an incompletely sampled early melanoma cannot be excluded. Management ranges from monitoring to complete excision or specialist pathology review.

Pigmented lesions

Melanocytic Hyperplasia

Melanocytic hyperplasia is a term from a pathology report: it means a pathologist has found an increased number — or an altered distribution — of melanocytes (the pigment-producing cells of the skin) in a biopsied mole or pigmented spot. It is usually a description rather than a single diagnosis. It does not mean you have melanoma, but depending on the exact wording it may not completely exclude an early one either, which is why treatment decisions can sometimes be difficult.

Portrait of Dr Christopher Irwin

By Dr Christopher Irwin, MBChB, FRACGP, MMed (Skin Cancer), FACAM, MSCCA

Last reviewed 2026-07-16 · Editorial policy

Quick definition

Melanocytic hyperplasia is a term from a pathology report. It means a pathologist has found an increased number — or an altered distribution — of melanocytes, the pigment-producing cells of the skin, in a biopsied mole or pigmented spot. It is usually a description rather than a single diagnosis: it does not by itself mean melanoma, but depending on the exact wording it may not completely exclude an early one either. This is why treatment decisions sometimes need careful judgement — weighing the exact pathology terms, the biopsy margins, how the lesion looked, its location and your personal melanoma risk.

What does melanocytic hyperplasia mean on a skin biopsy?

Melanocytic hyperplasia means that a pathologist has identified an increased number, or an altered distribution, of melanocytes — the pigment-producing cells in the skin. It is usually a microscopic finding described after a mole, freckle or other pigmented lesion has been biopsied or removed.

Importantly, melanocytic hyperplasia is often a description rather than one specific diagnosis. It does not automatically mean that you have melanoma. However, depending on the exact wording of the pathology report, it may also not provide complete certainty that the lesion is harmless.

This is why treatment decisions sometimes require careful consideration of:

  • The exact pathology findings
  • Whether the entire lesion was sampled
  • Whether abnormal cells extend to the biopsy edges
  • How the lesion appeared clinically and under dermoscopy
  • The lesion’s location
  • Your personal melanoma risk
  • The benefits and disadvantages of further surgery

At The Skin Doctor in Ivanhoe and Diamond Creek, we review the pathology result alongside the original appearance of the lesion and help determine whether further treatment or monitoring is appropriate.

What are melanocytes?

Melanocytes are specialised cells found mainly near the bottom of the epidermis, the outer layer of the skin. They produce melanin — the pigment that contributes to the colour of our skin, hair and eyes.

Melanocytes are also involved in:

  • Freckles and sunspots
  • Moles, also called melanocytic naevi
  • Some forms of pigmentation caused by sun exposure
  • Melanoma

Having increased melanocytes does not, by itself, mean that those cells are cancerous.

Is melanocytic hyperplasia melanoma?

No — not necessarily. Melanocytic hyperplasia is not the same diagnosis as invasive melanoma.

In many cases the finding represents a benign response to sun exposure, a change occurring around an otherwise benign mole, or a mildly atypical proliferation that is unlikely to cause harm.

The difficulty is that some early melanomas — particularly melanoma in situ or lentigo maligna — can begin as a subtle increase in melanocytes along the base of the epidermis. A small biopsy may occasionally capture only the less-developed part of a larger lesion.

The phrase therefore sometimes means:

The exact significance depends on whether the cells are described as normal-looking, mildly atypical or significantly atypical, and whether the pathologist believes the changes are reactive, benign, uncertain or suspicious.

Different terms that may appear in your pathology report

Pathology reports may use several related expressions, including:

  • Lentiginous melanocytic hyperplasia
  • Junctional melanocytic hyperplasia
  • Atypical lentiginous melanocytic hyperplasia
  • Atypical junctional melanocytic hyperplasia
  • Atypical melanocytic hyperplasia
  • Atypical intraepidermal melanocytic proliferation
  • Melanocytic proliferation of uncertain significance

These terms are not always interchangeable. For example, the word lentiginous describes melanocytes spreading individually along the lower layer of the epidermis, while junctional refers to melanocytes located around the junction between the epidermis and the dermis. In chronically sun-damaged skin, atypical lentiginous proliferations can be particularly difficult to interpret and are recognised as sitting on a spectrum with early lentiginous melanoma.3

The words atypical, uncertain or cannot exclude are particularly important. They indicate that the pathologist has seen features that are not completely routine, even though the threshold for a definite melanoma diagnosis may not have been reached.

Modern pathology classification systems recognise that some melanocytic lesions fall into an intermediate category where the microscopic features do not produce a completely certain answer — and that this residual uncertainty should be communicated clearly in the report.1

Why can treatment decisions be difficult?

1. Melanocytic lesions exist on a spectrum

Some lesions are clearly benign. Others are clearly melanoma. Between these groups are lesions with overlapping features.

Unlike a blood test with a simple positive or negative result, assessing a melanocytic lesion involves weighing:

  • The number and arrangement of melanocytes
  • The size and appearance of their nuclei
  • Whether they form nests
  • Whether they extend upwards through the epidermis
  • Whether they involve hair follicles or other skin structures
  • The degree of sun damage
  • Whether the lesion is symmetrical and well circumscribed

For some intermediate lesions, even experienced pathologists may reasonably differ in their interpretation.4 Consensus guidance specifically recognises that uncertainty can remain in high-grade or borderline melanocytic lesions and should be communicated in the pathology report.1

2. The biopsy only shows the tissue that was removed

A punch or shave biopsy may sample only part of a larger pigmented lesion.

One area may show relatively mild melanocytic hyperplasia while another part contains more significant atypia or melanoma in situ. Australian guidance therefore generally favours complete excision biopsy when melanoma is suspected, where this is practical and safe.2 An incisional (partial) biopsy may still be appropriate when a lesion is very large, located on the face, or situated somewhere that complete removal would be difficult or cosmetically significant — and the biopsy site must then be chosen carefully.

3. The pathology result must match the clinical appearance

Pathologists examine the cells under a microscope, but they may not have seen the original lesion on your skin.

Your treating doctor can consider additional information such as:

  • Whether the lesion was changing
  • Its size, shape and colour
  • Dermoscopic structures
  • Whether pigment remained after the biopsy
  • How the lesion compared with your other moles
  • Its location and pattern of sun exposure
  • Your personal and family melanoma history

A reassuring pathology description may need reconsideration when the original lesion appeared highly suspicious. Equally, an alarming-sounding pathology term may be less concerning when the lesion was completely removed and the overall clinical findings are reassuring.

4. The edges of the biopsy matter

If melanocytic hyperplasia is described as extending to a peripheral margin, it means the changes reach the side of the tissue sample.

This does not automatically mean that cancer has been left behind. It does mean the pathologist cannot see where the proliferation ends, because the edge of the lesion may lie outside the specimen.

Further treatment is more likely to be considered when:

  • Atypical cells extend to an edge
  • Visible pigment remains at the site
  • Only a small part of the lesion was sampled
  • The pathology report raises melanoma in situ as a possibility
  • The clinical and pathology findings do not agree

5. Treatment has consequences too

Removing additional skin provides more tissue for diagnosis and may eliminate a potentially important lesion. However, surgery can also cause:

  • A permanent scar
  • Bleeding or infection
  • Delayed healing
  • Distortion of nearby structures
  • A larger or more complex repair
  • Cosmetic changes, particularly on the face, nose, ears or eyelids

The safest decision is not always simply to remove the widest possible area. Treatment should be proportionate to the level of concern.

Can melanocytic hyperplasia be treated with laser, freezing or cream?

Destructive treatments are generally avoided while the diagnosis of a pigmented melanocytic lesion remains uncertain.

Laser, cryotherapy or cautery may destroy the visible pigmentation without providing a complete specimen for pathology. They can also make future clinical and microscopic assessment more difficult.

When melanoma or an atypical melanocytic proliferation is a possibility, obtaining adequate tissue and establishing the correct diagnosis is more important than simply removing the colour.

What happens at your appointment?

At The Skin Doctor, your assessment may involve:

  1. Reviewing the complete pathology report
  2. Examining the biopsy site and any remaining pigmentation
  3. Reviewing photographs or dermoscopic images taken before the biopsy
  4. Assessing your other moles and overall melanoma risk during a full skin check
  5. Determining whether the clinical and pathological findings agree
  6. Discussing monitoring, further biopsy, excision or pathology review
  7. Explaining the likely scar and repair before any additional procedure

Please bring a copy of your pathology report if the original biopsy was performed elsewhere. Previous photographs and details of any earlier biopsies from the same area are also helpful.

Melanocytic lesion assessment in Ivanhoe and Diamond Creek

Receiving an uncertain pathology result can be stressful. Terms such as “atypical proliferation” or “cannot exclude melanoma” may sound alarming, but they do not necessarily mean that melanoma has been diagnosed.

Our aim is to explain what the report means, identify what remains uncertain, and recommend a proportionate next step — whether that is review only, planned monitoring, or further surgery.

This information is general and cannot replace assessment of your individual lesion, pathology report and medical history.

Diagnosis

Melanocytic hyperplasia is not diagnosed on the skin — it is a microscopic finding a pathologist describes after a mole or pigmented spot has been biopsied. Making sense of it means reading the pathology report alongside the way the lesion originally looked. At The Skin Doctor in Ivanhoe and Diamond Creek we review the full report, examine the biopsy site and any remaining pigment, look back at any dermoscopic photographs taken before the biopsy, assess your other moles and overall melanoma risk, and judge whether the clinical and pathological pictures agree before recommending monitoring, further biopsy, excision or a specialist pathology review.

Treatment options

No further surgery

Appropriate when the proliferation appears benign or low-grade, the lesion has been completely removed, the clinical appearance was reassuring and the pathology margins are clear. The site is simply kept under review at future skin checks.

Clinical and dermoscopic monitoring →

Considered for selected low-risk lesions, particularly where more surgery would leave a significant scar. Monitoring is planned rather than informal — a baseline clinical and dermoscopic photograph, a defined review interval, and clear instructions to return sooner if the pigment, colour or shape changes. It is less suitable when significant atypia or residual pigment remains, or when melanoma is still a concern.

Complete excision or re-excision →

Recommended when the first biopsy sampled only part of the lesion, atypical melanocytes extend to a margin, pigment remains, the report cannot exclude an early melanoma, the features are high-grade, the lesion still looks concerning, or reliable monitoring would be difficult. The margin is individualised — mild hyperplasia is not treated the same way as melanoma in situ.

Additional biopsy or staged sampling

For a large facial lesion or a broad area of pigmentation, removing everything at once may not be the best first step. Further targeted biopsies can show whether the change is uniform or whether a more concerning area lies elsewhere within the lesion.

Specialist pathology review

A second opinion from a pathologist with particular expertise in melanocytic lesions is valuable when the terminology is uncertain, melanoma is in the differential, the proposed surgery would be extensive, or the clinical and pathological findings do not match. Extra stains or molecular tests can occasionally help, but no single test resolves every borderline lesion.

When to see a doctor

Arrange an earlier review if you notice any of the following at or near the biopsy site: pigment returning or spreading beyond the scar; increasing asymmetry; new black, grey, blue, red or white areas; continued enlargement; bleeding without a clear injury; a new lump developing within the site; a sore that does not heal; or any rapid or otherwise unexplained change. A changing lesion should always be reassessed — even when an earlier biopsy was reported as benign.

Frequently asked questions

  • Is melanocytic hyperplasia cancer?
    Not by itself. The term describes an increase, or an altered pattern, of melanocytes — the skin's pigment cells. Some cases are entirely benign, while atypical forms may need further assessment to exclude an early melanoma.
  • Does melanocytic hyperplasia turn into melanoma?
    The term covers a range of findings, so there is no single progression risk that applies to everyone. Many cases will never become melanoma. In others, the concern is that the biopsy may have captured only part of an early melanoma that was not completely sampled.
  • What does "atypical melanocytic hyperplasia" mean?
    It means the melanocytes have features that are not entirely normal, but the sample may not meet all of the criteria needed for a definite diagnosis of melanoma. The degree of atypia and the pathologist's comments are what matter most.
  • What does "cannot exclude melanoma in situ" mean?
    It means melanoma in situ was not proven, but the pathologist cannot safely rule it out from the tissue available. Further sampling, complete excision or specialist pathology review is commonly considered.
  • What does "present at the margin" mean?
    It means the melanocytic proliferation reaches the edge of the biopsy specimen, so the lesion may continue beyond the tissue that was removed.
  • Do I always need another excision?
    No. Some completely removed, low-grade and clinically reassuring lesions can simply be monitored. Further excision is more likely when the atypia is significant, the biopsy was incomplete, pigment remains, or melanoma cannot be excluded.
  • Can a pathologist always tell whether a lesion is melanoma?
    Most lesions can be classified confidently. However, certain early or borderline melanocytic lesions have overlapping features, and disagreement can occur even among experienced pathologists — which is why the clinical picture, and at times a second opinion, matter.
  • Should I get a second pathology opinion?
    A second opinion can help when the diagnosis is uncertain, when the pathology and the clinical appearance do not match, or when the proposed treatment would involve a large or cosmetically important excision.
  • Can the lesion simply be watched?
    Monitoring may be reasonable for selected low-risk lesions, but it should involve documented clinical or dermoscopic images and a planned review interval. It should not replace further investigation when melanoma remains a real possibility.
  • Where can I have melanocytic hyperplasia assessed?
    The doctors at The Skin Doctor in Ivanhoe and Diamond Creek assess pigmented lesions, biopsy results and uncertain melanocytic pathology findings. We can review the original lesion, the pathology wording, the margins and the treatment options before deciding whether further surgery is needed.

References

  1. Barnhill RL, Elder DE, Piepkorn MW, et al. Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis (MPATH-Dx) Classification Schema for Melanocytic Lesions: A Consensus Statement. JAMA Netw Open. 2023;6(1):e2250613.DOI: 10.1001/jamanetworkopen.2022.50613
  2. Cancer Council Australia Melanoma Guidelines Working Party. Clinical practice guidelines for the diagnosis and management of melanoma — optimal biopsy approach for a suspicious pigmented lesion. Cancer Council Australia & Melanoma Institute Australia. 2018.
  3. Kossard S. Atypical lentiginous junctional naevi of the elderly and melanoma. Australas J Dermatol. 2002;43(2):93-101.DOI: 10.1046/j.1440-0960.2002.t01-1-00568.x
  4. Elmore JG, Barnhill RL, Elder DE, et al. Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ. 2017;357:j2813.DOI: 10.1136/bmj.j2813

Related

Related conditions

Related treatments

Medically reviewed by Dr Christopher Irwin, MBChB, FRACGP, MMed (Skin Cancer), FACAM, MSCCA · Last reviewed 2026-07-16 · Editorial policy